LRI Investments LLC Invests $157,000 in IQVIA Holdings Inc. (NYSE:IQV)

LRI Investments LLC bought a new position in IQVIA Holdings Inc. (NYSE:IQV) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 622 shares of the medical research company’s stock, valued at approximately $157,000.

Other hedge funds also recently made changes to their positions in the company. Los Angeles Capital Management LLC lifted its stake in shares of IQVIA by 17.5% in the 4th quarter. Los Angeles Capital Management LLC now owns 118,616 shares of the medical research company’s stock worth $27,445,000 after acquiring an additional 17,677 shares during the period. Jennison Associates LLC lifted its stake in shares of IQVIA by 7.3% in the 1st quarter. Jennison Associates LLC now owns 140,914 shares of the medical research company’s stock worth $35,636,000 after acquiring an additional 9,578 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in shares of IQVIA by 4.0% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,418,392 shares of the medical research company’s stock valued at $532,070,000 after purchasing an additional 93,194 shares during the period. Cadian Capital Management LP acquired a new stake in shares of IQVIA in the fourth quarter valued at about $70,108,000. Finally, Nomura Holdings Inc. acquired a new stake in shares of IQVIA in the fourth quarter valued at about $857,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on IQV shares. Truist Financial raised their target price on shares of IQVIA from $292.00 to $300.00 and gave the company a “buy” rating in a report on Tuesday, July 23rd. StockNews.com upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a report on Monday, July 15th. Robert W. Baird boosted their target price on shares of IQVIA from $235.00 to $251.00 and gave the company a “neutral” rating in a report on Tuesday, July 23rd. Evercore ISI boosted their target price on shares of IQVIA from $230.00 to $270.00 and gave the company an “outperform” rating in a report on Tuesday, July 23rd. Finally, The Goldman Sachs Group assumed coverage on shares of IQVIA in a research report on Thursday, June 6th. They set a “buy” rating and a $270.00 price target on the stock. Four research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $263.56.

IQVIA Stock Performance

Shares of IQVIA stock traded up $7.38 during trading on Friday, hitting $239.67. 1,195,238 shares of the stock were exchanged, compared to its average volume of 1,420,984. The stock’s fifty day moving average is $220.23 and its 200 day moving average is $229.46. The stock has a market cap of $43.69 billion, a PE ratio of 32.74, a P/E/G ratio of 2.26 and a beta of 1.49. The company has a debt-to-equity ratio of 1.80, a quick ratio of 0.88 and a current ratio of 0.85. IQVIA Holdings Inc. has a 12 month low of $167.42 and a 12 month high of $261.73.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Monday, July 22nd. The medical research company reported $2.64 EPS for the quarter, topping the consensus estimate of $2.57 by $0.07. The business had revenue of $3.81 billion during the quarter, compared to analyst estimates of $3.79 billion. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. The company’s quarterly revenue was up 2.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.22 earnings per share. As a group, sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.21 EPS for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.